MITRITÍN > INDUSTRIES

Pharmaceutical Industry 

Vietnam’s pharmaceutical industry is undergoing robust development, fueled by a rising middle class, aging population, and government focus on healthcare expansion. As of 2023, the market is valued at approximately USD 7.7 billion and is expected to reach over USD 16 billion by 2030, with an annual growth rate of 8–10%. The sector includes drug manufacturing, distribution, retail pharmacy chains, and research and development, with increasing foreign participation.

Pharmaceutical Segments with Competitive Advantages in Vietnam

1. Generic Drug Manufacturing
   Vietnam has over 250 pharmaceutical manufacturing facilities, focusing primarily on generic medicines. Domestic companies such as Traphaco, DHG Pharma, and Imexpharm are expanding capacity and upgrading to WHO-GMP, EU-GMP standards.

2. Active Pharmaceutical Ingredients (API) and Intermediates
   While Vietnam still imports the majority of APIs, government initiatives now promote local production to reduce dependency and enhance drug security. Several FDI projects in API parks are underway.

3. Herbal and Traditional Medicine
   Vietnam has strong potential in herbal medicine due to its biodiversity. Products using ginseng, turmeric, and local medicinal plants are gaining traction domestically and in export markets.

4. Clinical Trials and R&D Outsourcing
   Vietnam is becoming a favorable destination for early-stage clinical trials, particularly for Asian populations. International pharma companies are investing in partnerships with hospitals and CROs.

Why Invest in Vietnam’s Pharmaceutical Sector ?

1. Growing Healthcare Demand
   An aging population and rising income levels have led to greater demand for chronic disease treatment, health supplements, and preventive medicines. Per capita pharmaceutical spending is expected to double by 2030.

2. Government Strategy for Industry Development
   Vietnam's “Pharmaceutical Industry Development Strategy to 2030” aims to achieve 80% domestic production of essential medicines and promote API localization and high-tech drug development.

3. Favorable Legal and Investment Framework
   The Law on Pharmacy, updated in 2016 and subsequent decrees, allows for foreign-invested manufacturing, R&D activities, and joint ventures in drug distribution under clear guidelines.

4. Strategic Access to ASEAN Markets
   Vietnam is a member of ASEAN Pharmaceutical Regulatory Harmonization, facilitating cross-border approvals and positioning Vietnam as a production base for regional exports.

How Mitritín Supports Pharmaceutical Investors ?

1. Project Sourcing and Investment Opportunities
   We identify strategic projects in industrial zones focused on pharmaceuticals and API production, especially those seeking joint ventures or foreign technology partners.

2. Licensing and Regulatory Support
   Mitritín assists with market entry, GMP certification processes (WHO, EU), import-export licenses, and Drug Registration Numbers (DRNs), ensuring timely approvals.

3. Clinical and Research Partnership Development
   We facilitate connections with hospitals, research institutions, and clinical trial networks to support local studies and product development in Vietnam.

4. Policy Navigation and Incentive Access
   Mitritín helps investors understand and apply tax incentives, land-use priorities, and green financing options for pharmaceutical projects under government support programs.
   
   

For investors interested in Vietnam’s high-potential pharma sector, Mitritín offers tailored insights, project briefs, and full-cycle support from strategy to operation. Contact us for advisory on manufacturing, R&D, or distribution ventures.

For more information or service inquiries, please contact us:

MITRITÍN VIETNAM LIMITED
The Firm of Strategy & Solutions

Address: 39 Le Hien Mai Str,  Cat Lai Ward,
Ho Chi Minh City, VIETNAM
Tel: +84 96 3939 247
Email:   This email address is being protected from spambots. You need JavaScript enabled to view it.  
Website: www.mitritin.com

~~~~~~~

BEYOND CHALLENGES